With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.6925-00-4,Quinoxaline-6-carboxylic acid,as a common compound, the synthetic route is as follows.
6925-00-4, Example 44 {(S)-3-[3-(4-Fluoro-phenyl)-1, 2, 4-oxadiazol-5-yl]-piperidin-1-yl}-quinoxalin-6-yl- methanone The compound was prepared following the procedure described in the Example 36, using 6-quinoxalinecarboxylic acid as the acid of choice and S-3- [3- (4-fluoro-phenyl)- [1, 2,4] oxadiazol-5-yl]-piperidine hydrochloride (prepared as described in the Example 12). {(S)-3-[3-(4-Fluoro-phenyl)-1, 2, 4-oxadiazol-5-yl]-piperidin-1-yl}-quinoxalin-6- yl-methanone was obtained pure after purification through a silica gel cartridge (eluent: DCM/MeOH/NH40H 98/2/0. 2). Yield: 83% (white solid); [a] o= +120 (c=1.0, CHC13) ; LCMS (Tr): 7.0 min (method A); MS (ES+) gave m/z : 404.0. 1H-NMR (CDC13, 330 K, 300 MHz), 8 (ppm): 8. 88 (s, 2H); 8. 18 (dd, 2H); 8. 06 (m, 2H); 7.82 (dd, 1H) ; 7.15 (dd, 2H); 4.47 (mbr, 1H); 4.02 (mbr, 1H) ; 3.65 (dd, 1H); 3.44-3. 23 (m, 2H) ; 2.36 (m, 1H) ; 2.14-1. 88 (m, 2H); 1.74 (m, 1H).
As the paragraph descriping shows that 6925-00-4 is playing an increasingly important role.
Reference£º
Patent; ADDEX PHARMACEUTICALS SA; WO2005/44797; (2005); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider